TY - JOUR
T1 - Primary care management of chronic obstructive pulmonary disease to reduce exacerbations and their consequences
AU - Anzueto, Antonio
N1 - Funding Information:
This review was developed on the basis of presentations and discussions at the Long-term Considerations in the Course and Treatment of COPD taskforce meeting in Miami, Florida, December 9 to December 10, 2008. This meeting, author’s participation and manuscript preparation were supported by Boehringer Ingelheim Pharmaceuticals and Pfizer. Medical writing assistance was provided by Kim Coleman Healy, PhD, of Envision Scientific Solutions. The review reflects the concepts of the author and is his sole responsibility. It was not reviewed by Boehringer Ingelheim Pharmaceuticals and Pfizer except to ensure medical and safety accuracy.
PY - 2010/10
Y1 - 2010/10
N2 - Exacerbations of chronic obstructive pulmonary disease (COPD)-acute worsenings of dyspnea, cough and/or sputum production beyond daily symptom variations, necessitating a change in treatment-account for most COPD-related morbidity, care burden and direct costs. Frequent exacerbations (especially those requiring emergency, inpatient or intensive care) reduce physical activity, accelerate lung function decline and increase mortality. This review profiles exacerbation diagnosis, treatment and reduction measures for primary care physicians. Chronic maintenance pharmacotherapy is important to reduce exacerbations. Tiotropium, a long-acting anticholinergic, and salmeterol/fluticasone, a long-acting β-agonist/inhaled corticosteroid combination, are Food and Drug Administration-approved maintenance therapies to reduce exacerbations of COPD. Influenza and pneumonia vaccinations reduce infectious triggers; pulmonary rehabilitation reduces exacerbation recurrence. Acute exacerbation treatment (short-acting bronchodilators, systemic corticosteroids and/or antibiotics) should be complemented by long-term COPD maintenance therapy to reduce future exacerbations. Recognition of a COPD exacerbation signals primary care physicians to establish long-term COPD management to reduce morbidity, disability and mortality.
AB - Exacerbations of chronic obstructive pulmonary disease (COPD)-acute worsenings of dyspnea, cough and/or sputum production beyond daily symptom variations, necessitating a change in treatment-account for most COPD-related morbidity, care burden and direct costs. Frequent exacerbations (especially those requiring emergency, inpatient or intensive care) reduce physical activity, accelerate lung function decline and increase mortality. This review profiles exacerbation diagnosis, treatment and reduction measures for primary care physicians. Chronic maintenance pharmacotherapy is important to reduce exacerbations. Tiotropium, a long-acting anticholinergic, and salmeterol/fluticasone, a long-acting β-agonist/inhaled corticosteroid combination, are Food and Drug Administration-approved maintenance therapies to reduce exacerbations of COPD. Influenza and pneumonia vaccinations reduce infectious triggers; pulmonary rehabilitation reduces exacerbation recurrence. Acute exacerbation treatment (short-acting bronchodilators, systemic corticosteroids and/or antibiotics) should be complemented by long-term COPD maintenance therapy to reduce future exacerbations. Recognition of a COPD exacerbation signals primary care physicians to establish long-term COPD management to reduce morbidity, disability and mortality.
KW - Chronic obstructive pulmonary disease
KW - Exacerbations
KW - Formoterol/budesonide
KW - Salmeterol/fluticasone
KW - Tiotropium
UR - http://www.scopus.com/inward/record.url?scp=77958017394&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77958017394&partnerID=8YFLogxK
U2 - 10.1097/MAJ.0b013e3181e40cd1
DO - 10.1097/MAJ.0b013e3181e40cd1
M3 - Review article
C2 - 20625276
AN - SCOPUS:77958017394
SN - 0002-9629
VL - 340
SP - 309
EP - 318
JO - American Journal of the Medical Sciences
JF - American Journal of the Medical Sciences
IS - 4
ER -